Herceptin: Mechanisms of action and resistance

Cancer Letters

Volumn 232, Issue 2, 2006, Pages 123-138

  Nahta, Rita ^a   Esteva, Francisco J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Breast; IGF IR; Monoclonal antibodies; p27 kip1; Trastuzumab; Tyrosine kinase receptor

Indexed keywords

ANTHRACYCLINE; CANERTINIB; CARBOPLATIN; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; GEFITINIB; GEMCITABINE; LAPATINIB; NAVELBINE; PACLITAXEL; PERTUZUMAB; TAXANE DERIVATIVE; TIPIFARNIB; TRASTUZUMAB;

ANGIOGENESIS; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; DISEASE COURSE; DNA SYNTHESIS INHIBITION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESISTANCE; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; IMMUNE RESPONSE; MONOTHERAPY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; SHORT SURVEY; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 31644439702     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.01.041     Document Type: Review

References (129)

1. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, and W.L. McGuire Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182
2. D.J. Slamon, W. Godolphin, L.A. Jones, J.A. Holt, S.G. Wong, and D.E. Keith Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 1989 707 712
3. R.M. Hudziak, J. Schlessinger, and A. Ullrich Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells Proc. Natl Acad. Sci. USA 84 1987 7159 7163
4. L. Bouchard, L. Lamarre, P.J. Tremblay, and P. Jolicoeur Stochastic appearance of mammary tumors in transgenic mice carrying the mmtv/c-neu oncogene Cell 57 1989 931 936
5. C.T. Guy, M.A. Webster, M. Schaller, T.J. Parsons, R.D. Cardiff, and W.J. Muller Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease Proc. Natl Acad. Sci. USA 89 1992 10578 10582
6. C.T. Guy, R.D. Cardiff, and W.J. Muller Activated neu induces rapid tumor progression J. Biol. Chem. 271 1996 7673 7678
7. P. Depowski, D. Mulford, D. Minot, P. Bourne, C. McCabe, and L. McHugh Comparative analysis of Her-2/neu protein overexpression in breast cancer using paraffin-embedded tissue and cytologic specimens Mod. Pathol. 15 2002 70A
8. H. Joensuu, J. Isola, M. Lundin, T. Salminen, K. Holli, and V. Kataja Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study Clin. Cancer Res. 9 2003 923 930
9. D.S. Leonard, A.D. Hill, L. Kelly, B. Dijkstra, E. McDermott, and N.J. O'Higgins Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer Br. J. Surg. 89 2002 262 271
10. M.F. Press, L. Bernstein, P.A. Thomas, L.F. Meisner, J.Y. Zhou, and Y. Ma HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas J. Clin. Oncol. 15 1997 2894 2904
11. M.F. Press, D.J. Slamon, K.J. Flom, J. Park, J.Y. Zhou, and L. Bernstein Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens J. Clin. Oncol. 20 2002 3095 3105
12. H.B. Muss, A.D. Thor, D.A. Berry, T. Kute, E.T. Liu, and F. Koerner c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer New Engl. J. Med. 330 1994 1260 1266
13. S. Paik, J. Bryant, C. Park, B. Fisher, E. Tan-Chiu, and D. Hyams erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer J. Natl Cancer Inst. 90 1998 1361 1370
14. A.D. Thor, D.A. Berry, D.R. Budman, H.B. Muss, T. Kute, and I.C. Henderson erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer J. Natl. Cancer Inst. 90 1998 1346 1360
15. S.A. Eceles The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis J. Mamm. Gland Biol. Neoplasia 6 2001 393 406
16. S. Paik, R. Hazan, E.R. Fisher, R.E. Sass, B. Fisher, and C. Redmond Pathologic findings from the national surgical adjuvant breast and bowel project: prognostic significance of erbB-2 protein overexpression in primary breast cancer J. Clin. Oncol. 8 1990 103 112
17. G.A. Niehans, T.P. Singleton, D. Dykoski, and D.T. Kiang Stability of HER-2/neu expression over time and at multiple metastatic sites J. Natl Cancer Inst. 85 1993 1230 1235
18. P. Carter, L. Presta, C.M. Gorman, J.B. Ridgway, D. Henner, and W.L. Wong Humanization of an anti-p185her2 antibody for human cancer therapy Proc. Natl Acad. Sci. USA 89 1992 4285 4289
19. J. Baselga, J. Albanell, M.A. Molina, and J. Arribas Mechanism of action of trastuzumab and scientific update Semin. Oncol. 28 2001 4 11
20. M.X. Sliwkowski, J.A. Lofgren, G.D. Lewis, T.E. Hotaling, B.M. Fendly, and J.A. Fox Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin) Semin. Oncol. 26 1999 60 70
21. X.F. Le, F.X. Claret, A. Lammayot, L. Tian, D. Deshpande, and R. Lapushin The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition J. Biol. Chem. 278 2003 23441 23450
22. R. Nahta, T. Takahashi, N.T. Ueno, M.C. Hung, and F.J. Esteva P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells Cancer Res. 64 2004 3981 3986
23. R. Nahta, M.C. Hung, and F.J. Esteva The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells Cancer Res. 64 2004 2343 2346
24. Y. Nagata, K.H. Lan, X. Zhou, M. Tan, F.J. Esteva, and A.A. Sahin PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Cancer Cell 6 2004 117 127
25. H.A. Lane, I. Beuvink, A.B. Motoyama, J.M. Daly, R.M. Neve, and N.E. Hynes ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency Mol. Cell Biol. 20 2000 3210 3223
26. H.A. Lane, A.B. Motoyama, I. Beuvink, and N.E. Hynes Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling Ann. Oncol. 12 2001 21 22
27. J.C. Chang, S. Mohsin, H. Weiss, S.G. Hilsenbeck, C. Guttierez, and A. Lucci Induction of apoptosis without change in cell proliferation in primary breast cancers with neoadjuvant trastuzumab Breast Cancer Res. Treat. 82 2003 24
28. R. Gennari, S. Menard, F. Fagnoni, L. Ponchio, M. Scelsi, and E. Tagliabue Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2 Clin. Cancer Res. 10 2004 5650 5655
29. E. Laughner, P. Taghavi, K. Chiles, P.C. Mahon, and G.L. Semenza HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1 alpha (HIF-1 alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression Mol. Cell Biol. 21 2001 3995 4004
30. L. Yen, X.L. You, A.E. Al Moustafa, G. Batist, N.E. Hynes, and S. Mader Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis Oncogene 19 2000 3460 3469
31. Y. Izumi, L. Xu, E. di Tomaso, D. Fukumura, and R.K. Jain Tumour biology: Herceptin acts as an anti-angiogenic cocktail Nature 416 2002 279 280
32. K.S. Klos, X. Zhou, S. Lee, L. Zhang, W. Yang, and Y. Nagata Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone Cancer 98 2003 1377 1385
33. A.M. Petit, J. Rak, M.C. Hung, P. Rockwell, N. Goldstein, and B. Fendly Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors Am. J. Pathol. 151 1997 1523 1530
34. S. Cooley, L.J. Burns, T. Repka, and J.S. Miller Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu Exp. Hematol. 27 1999 1533 1541
35. G.D. Lewis, I. Figari, B. Fendly, W.L. Wong, P. Carter, and C. Gorman Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies Cancer Immunol. Immunother. 37 1993 255 263
36. R.A. Clynes, T.L. Towers, L.G. Presta, and J.V. Ravetch Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets Nat. Med. 6 2000 443 446
37. T. Repka, E.G. Chiorean, J. Gay, K.E. Herwig, V.K. Kohl, and D. Yee Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study Clin. Cancer Res. 9 2003 2440 2446
38. Y.Z. Lin, and G.M. Clinton A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells Oncogene 6 1991 639 643
39. S.M. Pupa, S. Menard, D. Morelli, B. Pozzi, G. De Palo, and M.I. Colnaghi The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage Oncogene 8 1993 2917 2923
40. J.R. Zabrecky, T. Lam, S.J. McKenzie, and W. Carney The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, sk-br-3 J. Biol. Chem. 266 1991 1716 1720
41. T.A. Christianson, J.K. Doherty, Y.J. Lin, E.E. Ramsey, R. Holmes, and E.J. Keenan NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer Cancer Res. 58 1998 5123 5129
42. R. Colomer, S. Montero, A. Lluch, B. Ojeda, A. Barnadas, and A. Casado Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer Clin. Cancer Res. 6 2000 2356 2362
43. K. Leitzel, Y. Teramoto, K. Konrad, V.M. Chinchilli, G. Volas, and H. Grossberg Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer J. Clin. Oncol. 13 1995 1129 1135
44. H. Yamauchi, A. O'Neill, R. Gelman, W. Carney, S. Hosch, and D.W. Kufe Elevated circulating HER-2/neu-related protein (NRP) is associated with low response rate (RR) to first-line hormone therapy (HT) in patients with estrogen and/or progesterone receptor positive (ER, PR Pos) advanced breast cancer (AdBrCA) (Meeting abstract) Proc. Am. Soc. Clin. Oncol. 15 1996 A116
45. M.A. Molina, R. Saez, E.E. Ramsey, M.J. Garcia-Barchino, F. Rojo, and A.J. Evans NH2-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer Clin. Cancer Res. 8 2002 347 353
46. M.A. Molina, J. Codony-Servat, J. Albanell, F. Rojo, J. Arribas, and J. Baselga Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells Cancer Res. 61 2001 4744 4749
47. F.J. Esteva, C. Cheli, H.A. Fritsche, M. Fornier, D.J. Slamon, and R.P. Thiel Clinical utility of circulating HER-2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients undergoing trastuzumab-based therapy Breast Can. Res. Treat. 88 2004 6001
48. F.J. Esteva, V. Valero, D. Booser, L.T. Guerra, J.L. Murray, and L. Pusztai Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer J. Clin. Oncol. 20 2002 1800 1808
49. M. Pegram, S. Hsu, G. Lewis, R. Pietras, M. Beryt, and M. Sliwkowski Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers Oncogene 18 1999 2241 2251
50. M.D. Pegram, G.E. Konecny, C. O'Callaghan, M. Beryt, R. Pietras, and D.J. Slamon Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer J. Natl Cancer Inst. 96 2004 739 749
51. R.J. Pietras, B.M. Fendly, V.R. Chazin, M.D. Pegram, S.B. Howell, and D.J. Slamon Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells Oncogene 9 1994 1829 1838
52. R.J. Pietras, M.D. Pegram, R.S. Finn, D.A. Maneval, and D.J. Slamon Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs Oncogene 17 1998 2235 2249
53. R.J. Pietras, J.C. Poen, D. Gallardo, P.N. Wongvipat, H.J. Lee, and D.J. Slamon Monoclonal antibody to HER-2/neu receptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene Cancer Res. 59 1999 1347 1355
54. S. Mayfield, J.P. Vaughn, and T.E. Kute DNA strand breaks and cell cycle perturbation in Herceptin treated breast cancer cell lines Breast Cancer Res. Treat. 70 2001 123 129
55. P. Kauraniemi, S. Hautaniemi, R. Autio, J. Astola, O. Monni, and A. Elkahloun Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines Oncogene 23 2004 1010 1013
56. R.C. Bast, P. Ravdin, D.F. Hayes, S. Bates, H. Fritsche, and J.M. Jessup 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American society of clinical oncology J. Clin. Oncol. 19 2001 1865 1878
57. M. Bilous Predicting HER2 status of breast cancer from basic pathology features: HER2 status of 1500 breast cancers determined by immunohistochemistry and fluorescence in situ hybridisation with pathology correlation Eur. J. Cancer 38 2002 S52
58. M. Fornier, M. Risio, C. Van Poznak, and A. Seidman HER2 testing and correlation with efficacy of trastuzumab therapy Oncology (Huntingt.) 16 2002 1340 1342
59. G. Pauletti, S. Dandekar, H. Rong, L. Ramos, H. Peng, and R. Seshadri Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry J. Clin. Oncol. 18 2000 3651 3664
60. G. Schaller, K. Evers, S. Papadopoulos, A. Ebert, and H. Buhler Current use of HER2 tests Ann. Oncol. 12 2001 S97 S100
61. A.D. Seidman, M. Fornier, F.J. Esteva, L. Tan, S. Kaptain, and A. Bach Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification J. Clin. Oncol. 19 2001 2587 2595
62. D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, and A. Bajamonde Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 New Engl. J. Med. 344 2001 783 792
63. C.L. Vogel, M.A. Cobleigh, D. Tripathy, J.C. Gutheil, L.N. Harris, and L. Fehrenbacher Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J. Clin. Oncol. 20 2002 719 726
64. D.L. Persons, M.M. Bui, M.C. Lowery, H.F. Mark, J.F. Yung, and J.M. Birkmeier Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: a multicenter portability study Ann. Clin. Lab. Sci. 30 2000 41 48
65. R.D. Mass, M. Press, S. Anderson, M. Murphy, and D. Slamon Improved survival benefit from Herceptin (tumour biology: Herceptin acts as an anti-angiogenic cocktail trastuzumab) in patients selected by fluorescence in situ hybridization (FISH) Proc. Am. Soc. Clin. Oncol. 20 2001 85
66. L.N. Harris, V. Liotcheva, G. Broadwater, M.J. Ramirez, P. Maimonis, and S. Anderson Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy J. Clin. Oncol. 19 2001 1698 1706
67. T.W. Jacobs, A.M. Gown, H. Yaziji, M.J. Barnes, and S.J. Schnitt Specificity of HercepTest in determining HER-2/neu status of breast cancers using the united states food and drug administration-approved scoring system J. Clin. Oncol. 17 1999 1983 1987
68. F.J. Esteva, A.A. Sahin, K. Coombes, J. Baker, M. Cronin, and M. Walker Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients - M.D. Anderson clinical validation study Breast Cancer Res. Treat. 82 2003 A17
69. W.J. Kostler, B. Schwab, C.F. Singer, R. Neumann, E. Rucklinger, and T. Brodowicz Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer Clin. Cancer Res. 10 2004 1618 1624
70. J. Baselga Phase I and II clinical trials of trastuzumab Ann. Oncol. 12 2001 49 55
71. J. Baselga, D. Tripathy, J. Mendelsohn, S. Baughman, C.C. Benz, and L. Dantis Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer J. Clin. Oncol. 14 1996 737 744
72. M.A. Cobleigh, C.L. Vogel, D. Tripathy, N.J. Robert, S. Scholl, and L. Fehrenbacher Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER-2 overexpressing metastatic breast cancer that has progresssed after chemotherapy for metastatic disease J. Clin. Oncol. 17 1999 2639 2648
73. D.L. Keefe Trastuzumab-associated cardiotoxicity Cancer 95 2002 1592 1600
74. A. Seidman, C. Hudis, M.K. Pierri, S. Shak, V. Paton, and M. Ashby Cardiac dysfunction in the trastuzumab clinical trials experience J. Clin. Oncol. 20 2002 1215 1221
75. C. Ozcelik, B. Erdmann, B. Pilz, N. Wettschureck, S. Britsch, and N. Hubner Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy Proc. Natl Acad. Sci. USA. 99 2002 8880 8885
76. E.P. Winer, and H.J. Burstein New combinations with Herceptin((R)) in metastatic breast cancer Oncology 61 2001 50 57
77. M.D. Pegram, A. Lipton, D.F. Hayes, B.L. Weber, J.M. Baselga, and D. Tripathy Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment J. Clin. Oncol. 16 1998 2659 2671
78. H.J. Burstein, I. Kuter, S.M. Campos, R.S. Gelman, L. Tribou, and L.M. Parker Clinical activity of trastuzumab and vinorelbine in women with HER-2 overexpressing metastatic breast cancer J. Clin. Oncol. 19 2001 2722 2730
79. J.A. O'Shaughnessy, S. Vukelja, T. Marsland, G. Kimmel, S. Ratnam, and J. Pippen Gemcitabine and trastuzamab for HER-2 positive metastatic breast cancer: preliminary results of a phase II study Breast Cancer Res. Treat. 69 2001 302
80. G. Konecny, M. Fritz, M. Untch, A. Lebeau, M. Felber, and S. Lude HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer Breast Cancer Res. Treat. 69 2001 53 63
81. M.D. Pegram, A. Lopez, G. Konecny, and D.J. Slamon Trastuzumab and chemotherapeutics: drug interactions and synergies Semin. Oncol. 27 2000 21 25
82. J.M. Nabholtz Preliminary results of two open-label multicenter pilot phase II trials with Herceptin in combination with docetaxel and platinum salts (cis- or carboplatin) (TCH) as therapy for advanced breast cancer in women with overexpresing HER2/neu Breast Cancer Res. Treat. 58 2000 327
83. N. Robert, B. Leyland-Jones, L. Asmar, R. Belt, D. Ilegbodu, and D. Loesch Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER2/Neu positive advanced breast cancer Breast Cancer Res. Treat. 76 2002 35
84. D.J. Slamon, R. Patel, R. Northfelt, M. Pegram, J. Rubin, and G. Sebastian Phase II pilot study of Herceptin combined with taxotere and carboplatin in metastatic breast cancer patients overexpressing the HER2-neu proto-oncogene: a pilot study of the UCLA network Proc. Am. Soc. Clin. Oncol. 20 2001 193
85. S. Paik, J. Bryant, E. Tan-Chiu, E. Romond, W. Hiller, and K. Park Real-world performance of HER2 testing - national surgical adjuvant breast and bowel project experience J. Natl Cancer Inst. 94 2002 852 854
86. P.C. Roche, V.J. Suman, R.B. Jenkins, N.E. Davidson, S. Martino, and P.A. Kaufman Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831 J. Natl Cancer Inst. 94 2002 855 857
87. H.J. Burstein, L.N. Harris, R. Gelman, S.C. Lester, R.A. Nunes, and C.M. Kaelin Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study J. Clin. Oncol. 21 2003 46 53
88. A.U. Buzdar, K. Hunt, T. Smith, D. Francis, M. Ewer, and D. Booser Significantly higher pathological complete remission (PCR) rate following neoadjuvant therapy with trastuzumab (H), paclitaxel (P), and anthracycline-containing chemotherapy (CT): initial results of a randomized trial in operable breast cancer (BC) with HER/2 positive disease J. Clin. Oncol. 22 2004 520
89. J.G. Paez, P.A. Janne, J.C. Lee, S. Tracy, H. Greulich, and S. Gabriel EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
90. P. Stephens, C. Hunter, G. Bignell, S. Edkins, H. Davies, and J. Teague Lung cancer: intragenic ERBB2 kinase mutations in tumours Nature 431 2004 525 526
91. H.J. Burstein, L.N. Harris, P.K. Marcom, R. Lambert-Falls, K. Havlin, and B. Overmoyer Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm J. Clin. Oncol. 21 2003 2889 2895
92. D. Graus-Porta, R.R. Beerli, J.M. Daly, and N.E. Hynes ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling Eur. Med. Biol. Org. J. 16 1997 1647 1655
93. S.S. Bacus, Y. Smith, Y. Yarden, and N. Spector Differences in response of breast cancer molecular profiles of patients likely to respond to either tyrosine kinase inhibitors or to erbB targeted therapies J. Clin. Oncol. 22 2004 3097
94. F.M. Yakes, W. Chinratanalab, C.A. Ritter, W. King, S. Seelig, and C.L. Arteaga Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action Cancer Res. 62 2002 4132 4141
95. T. Kute, C.M. Lack, M. Willingham, B. Bishwokama, H. Williams, and K. Barrett Development of Herceptin resistance in breast cancer cells Cytometry 57A 2004 86 93
96. D. Yee The insulin-like growth factor system as a treatment target in breast cancer Semin. Oncol. 29 2002 86 95
97. Y.H. Lu, X.L. Zi, Y.H. Zhao, D. Mascarenhas, and M. Pollak Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin) J. Natl Cancer Inst. 93 2001 1852 1857
98. R. Nahta, and F.J. Esteva HER-2-targeted therapy: lessons learned and future directions Clin. Cancer Res. 9 2003 5078 5084
99. S.L. Moulder, F.M. Yakes, S.K. Muthuswamy, R. Bianco, J.F. Simpson, and C.L. Arteaga Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo Cancer Res. 61 2001 8887 8895
100. G. Arpino, H. Weiss, A.E. Wakeling, K. Osborne, and R. Schiff Complete disappearance of ER+/HER2+ breast cancer xenografts with the combination of gefitinib, trastuzumab, and pertuzumab to block HER2 cross-talk with ER and restore tamoxifen inhibition Breast Cancer Res. Treat. 88 2004 23
101. L.R. Kelland, V. Smith, M. Valenti, L. Patterson, P.A. Clarke, and S. Detre Preclinical antitumor activity and pharmacodynamic studies with the farnesylprotein transferase inhibitor R115777 in human breast cancer Clin. Cancer Res. 7 2001 3544 3550
102. R. Nahta, J.D. Iglehart, B. Kempkes, and E.V. Schmidt Rate-limiting effects of cyclin D1 in transformation by ErbB2 predicts synergy between Herceptin and flavopiridol Cancer Res. 62 2002 2267 2271
103. R. Nahta, G.N. Hortobagyi, and F.J. Esteva Growth factor receptors in breast cancer: potential for therapeutic intervention Oncologist 8 2003 5 17
104. K. Wu, C. Wang, M. D'Amico, R.J. Lee, C. Albanese, and R.G. Pestell Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways Mol. Cancer Ther. 1 2002 695 706
105. M. Hidalgo, and E.K. Rowinsky The rapamycin-sensitive signal transduction pathway as a target for cancer therapy Oncogene 19 2000 6680 6686
106. S. Chan, S. Johnson, and M.E. Scheulen First report: a phase 2 study of the safety and activity of CCI-779 for patients with locally advanced or metastatic breast cancer failing prior chemotherapy Proc. Am. Soc. Clin. Oncol. 2002 175
107. F.J. Esteva Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancer The Oncologist 9 2004 4 9
108. D.B. Agus, R.W. Akita, W.D. Fox, G.D. Lewis, B. Higgins, and P.I. Pisacane Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth Cancer Cell 2 2002 127 137
109. H.S. Cho, K. Mason, K.X. Ramyar, A.M. Stanley, S.B. Gabelli, and D.W.J. Denney Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab Nature 421 2003 756 760
110. J.K. Batra, P.G. Kasprzyk, R.E. Bird, I. Pastan, and C.R. King Recombinant anti-erbB-2 immunotoxins containing pseudomonas exotoxin Proc. Natl Acad. Sci. USA 89 1992 5867 5871
111. M.G. Rosenblum, L.K. Shawver, J.W. Marks, J. Brink, L. Cheung, and B. Langton-Webster Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models Clin. Cancer Res. 5 1999 865 874
112. M.G. Rosenblum, S.A. Horn, and L.H. Cheung A novel recombinant fusion toxin targeting HER-2/NEU-over-expressing cells and containing human tumor necrosis factor Int. J. Cancer 88 2000 267 273
113. W. Wels, I.M. Harwerth, M. Mueller, B. Groner, and N.E. Hynes Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor Cancer Res. 52 1992 6310 6317
114. C.R. King, P.H. Fischer, R.F. Rando, and I. Pastan The performance of e23(Fv)PE, recombinant toxins targeting the erbB-2 protein Semin. Cancer Biol. 7 1996 79 86
115. Y. Reiter, R.J. Kreitman, U. Brinkmann, and I. Pastan Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated pseudomonas exotoxin Int. J. Cancer 58 1994 142 149
116. D.W. Rusnak, K. Affleck, S.G. Cockerill, C. Stubberfield, R. Harris, and M. Page The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer Cancer Res. 61 2001 7196 7203
117. L.F. Allen, P.F. Lenehan, I.A. Eiseman, W.L. Elliott, and D.W. Fry Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer Semin. Oncol. 29 2002 11 21
118. W. Xia, R.J. Mullin, B.R. Keith, L.H. Liu, H. Ma, and D.W. Rusnak Anti-tumor activity of GW57: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways Oncogene 21 2002 6255 6263
119. K.L. Blackwell, E.H. Kaplan, S.X. Franco, P.K. Marcom, J.E. Maleski, and N.L. Spector Determining molecular phenotypes of metastatic breast cancer that respond to the small molecule inhibitor of ErbB1 and ErbB2, lapatinib (GW572016) Breast Cancer Res. Treat. 88 2004 302
120. D. Yu, T.-C. Suen, D.-H. Yan, L.-S. Chang, and M.-C. Hung Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products Proc. Natl Acad. Sci. USA 87 1990 4499 4503
121. D. Yu, A. Matin, W. Xia, F. Sorgi, L. Huang, and M.C. Hung Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu Oncogene 11 1995 1383 1388
122. G.N. Hortobagyi, N.T. Ueno, W.Y. Xia, S. Zhang, J.K. Wolf, and J.B. Putnam Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial J. Clin. Oncol. 19 2001 3422 3433
123. L.M. Weiner, M. Holmes, G.P. Adams, F. LaCreta, P. Watts, and I. Garcia de Palazzo A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16 Cancer Res. 53 1993 94 100
124. M.R. Shalaby, P. Carter, D. Maneval, D. Giltinan, and C. Kotts Bispecific HER2 x CD3 antibodies enhance T-cell cytotoxicity in vitro and localize to HER2-overexpressing xenografts in nude mice Clin. Immunol. Immunopathol. 74 1995 185 192
125. L.M. Weiner, J.I. Clark, M. Davey, W.S. Li, I. Garcia de Palazzo, and D.B. Ring Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII Cancer Res. 55 1995 4586 4593
126. L.M. Weiner, J.I. Clark, D.B. Ring, and R.K. Alpaugh Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII J. Hematother. 4 1995 453 456
127. K.L. Knutson, K. Schiffman, M.A. Cheever, and M.L. Disis Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity Clin. Cancer Res. 8 2002 1014 1018
128. H. Bernhard, L. Salazar, K. Schiffman, A. Smorlesi, B. Schmidt, and K.L. Knutson Vaccination against HER-2/neu oncogenic protein Endocr. Relat. Cancer 9 2002 33 44
129. M.L. Disis, T.A. Gooley, K. Rinn, D. Davis, M. Piepkorn, and M.A. Cheever Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines J. Clin. Oncol. 20 2002 2624 2632